Ampio Pharmaceuticals Inc Stock Ownership - Who owns Ampio Pharmaceuticals?

Insider buying vs selling

Have Ampio Pharmaceuticals Inc insiders been buying or selling?
Michael A. MartinoCEO2023-05-2476,890$0.29
J. Kevin BuchiDirector2023-05-1632,534$0.27
J. Kevin BuchiDirector2023-05-1544,026$0.25
J. Kevin BuchiDirector2023-05-1223,440$0.24
David R. StevensDirector2023-05-1245,000$0.22
David R. StevensDirector2023-05-1125,000$0.22
David R. StevensDirector2023-05-1125,000$0.22

1 of 1

AMPE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AMPE insiders and whales buy or sell their stock.

AMPE Shareholders

What type of owners hold Ampio Pharmaceuticals Inc stock?
Michael MacAluso17.38%2,624,882$787.46kInsider
Vaughan Lennox Clift3.81%575,000$172.50kInsider
Holli Cherevka2.72%410,820$123.25kInsider
Richard B. Giles2.43%367,121$110.14kInsider
Donald B. Wingerter Jr.2.15%325,000$97.50kInsider
Dan Stokely2.07%312,274$93.68kInsider
Hrt Financial LP1.44%217,052$65.12kInstitution
Philip H. Coelho1.35%203,500$61.05kInsider
David R. Stevens0.69%103,971$31.19kInsider
J. Kevin Buchi0.66%100,000$30.00kInsider

1 of 3

AMPE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AMPE3.44%34.51%Net BuyingNet Buying
LEXX11.34%9.72%Net Buying
QLGN0.44%99.56%Net Buying
ARTL1.67%29.20%Net Buying

Ampio Pharmaceuticals Stock Ownership FAQ

Who owns Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSEMKT: AMPE) is owned by 3.44% institutional shareholders, 34.51% Ampio Pharmaceuticals insiders, and 62.05% retail investors. Michael MacAluso is the largest individual Ampio Pharmaceuticals shareholder, owning 2.62M shares representing 17.38% of the company. Michael MacAluso's Ampio Pharmaceuticals shares are currently valued at $787.46k.

If you're new to stock investing, here's how to buy Ampio Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.